MELI heads into Q4 earnings with strong top-line momentum, but rising costs and fierce competition may test margins.

West Pharmaceutical heads into Q4 with HVP demand likely lifting margins, but tariff risk looms as revenue and EPS targets come into focus.

TDOC heads into Q4 earnings with an improving loss outlook and rising Integrated Care EBITDA, but BetterHelp declines may weigh on revenues.

TDOC heads into Q4 earnings with an improving loss outlook and rising Integrated Care EBITDA, but BetterHelp declines may weigh on revenues.

OPXS' Q1 earnings per share fall sharply year over year despite double-digit revenue growth, as higher gold costs, legacy contract pressures and...

OPXS' Q1 earnings per share fall sharply year over year despite double-digit revenue growth, as higher gold costs, legacy contract pressures and...

UHS heads into Q4 earnings with strong Acute Care and Behavioral growth, but rising labor and supply costs could cloud a potential beat.

UHS heads into Q4 earnings with strong Acute Care and Behavioral growth, but rising labor and supply costs could cloud a potential beat.

BUD heads into Q4 earnings with expectations for revenue and EPS growth, but volume pressures, costs and macro headwinds could test investor optimism.

FIS heads into Q4 earnings with banking and capital markets growth set to boost revenue and EBITDA, though rising costs could partly offset positives.